Comparison of the cardiac effects of the antimalarials co-artemether and halofantrine in healthy participants

American Journal of Tropical Medicine and Hygiene

Volumn 66, Issue 3, 2002, Pages 293-298

  Bindschedler, Margaretha ^a   Lefèvre, Gilbert ^a   Degen, Peter ^a   Sioufi, Antoine ^a  

^a Novartis Institutes for BioMedical Research   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; HALOFANTRINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR RESPONSE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; ELECTROCARDIOGRAM; HUMAN; HUMAN EXPERIMENT; MALARIA FALCIPARUM; MALE; NORMAL HUMAN; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RR INTERVAL; TABLET;

PROTOZOA;

EID: 0036309852     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2002.66.293     Document Type: Article

References (32)

1. Status of antimalarial drugs under development
2. Clinical trial of artesunate and artemether on multidrug resistant falciparum malaria in Thailand. A preliminary report
3. Pharmacokinetics of mefloquine alone or in combination with artesunate
4. The treatment of malaria
5. Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria
6. Fatal neurotoxicity of arteether and artemether
7. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria
8. Clinical pharmacokinetics of artemether and lumefantrine (Riamet®)
9. Pharmacokinetic interaction trial between coartemether and mefloquine
10. Clinical pharmacokinetics of halofantrine
11. Pharmacokinetics of halofantrine and n-desbutylhalofantrine in patients with falciparum malaria following a multiple dose regimen of halofantrine
12. Pharmacokinetics of halofantrine in man: Effects of food and dose size
13. Determination of artemether and its metabolite, dihydroartemisinin, in plasma by high-performance liquid chromatography and electrochemical detection in the reductive mode
14. Analytical methods validation: Bioavailability, bioequivalence, and pharmacokinetic studies
15. Determination of a new antimalarial drug, benflumetol, in blood plasma by reverse-phase highperformance liquid chromatography with ultraviolet detection
16. An improved high-performance liquid chromatographic method for the simultaneous measurement of halofantrine and desbutylhalofantrine in human serum
17. Cardiac effects of standard-dose halofantrine therapy
18. Cardiac effect of halofantrine
19. Cardiac effects of halofantrine in children suffering from acute uncomplicated falciparum malaria
20. Provocation of ventricular tachycardia by antimalarial drug halofantrine in congenital long QT syndrome
21. Prolonged QT-interval with halofantrine
22. Prolonged QT-interval with halofantrine
23. Arythmies ventriculaires et prise d'halofantrine. Effet délètère probable. A propos de 3 observations
24. Cardiac effects of antimalarial treatment with halofantrine
25. Pharmacokinetics in Thai patients with acute uncomplicate falciparum malaria
26. Cardiac complications of halofantrine: A prospective study in 20 patients
27. Cardiac effects of co-artemether (artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers
28. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria
29. An integrated assessment of the clinical safety of artemetherlumefantrine: A new oral fixed dose-combination antimalarial drug
30. No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine
31. A clinical and pharmacokinetic trial of six doses of artemether-lumefanrine for multidrug resistant Plasmodium falciparum malaria in Thailand